Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.33)
# 3,359
Out of 4,840 analysts
25
Total ratings
52.94%
Success rate
-9.25%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $1.75 | +2,757.14% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $44.00 | +13.64% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $96.78 | -4.94% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $30.58 | -34.60% | 1 | Mar 31, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $120.18 | +8.17% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $13.42 | +272.58% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $34.57 | -27.68% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $6.27 | +1,096.17% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $57.55 | +73.76% | 1 | Mar 1, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $588.34 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $1,720 → $2,000 | $4.99 | +39,980.16% | 2 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $64.25 | +32.30% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.75
Upside: +2,757.14%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $44.00
Upside: +13.64%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $96.78
Upside: -4.94%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $30.58
Upside: -34.60%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $120.18
Upside: +8.17%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $13.42
Upside: +272.58%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $34.57
Upside: -27.68%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $6.27
Upside: +1,096.17%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $57.55
Upside: +73.76%
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $588.34
Upside: -
Feb 3, 2020
Upgrades: Outperform
Price Target: $1,720 → $2,000
Current: $4.99
Upside: +39,980.16%
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $64.25
Upside: +32.30%